CD24-targeting drug delivery system enhanced effect of cisplatin-resistant ovarian cancer cells

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462621
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Osaka Medical College
• Principal Investigator: TERAI YOSHITO 大阪医科大学, 医学部, 准教授 (90278531)
• Co-Investigator(Kenkyū-buntansha): Ohmichi Masahide 大阪医科大学, 医学部, 教授 (10283764) ; Kanemura Masanori 大阪医科大学, 医学部, 講師 (40298782) ; Tanabe Akiko 大阪医科大学, 医学部, 講師 (70454543) ; Yamashita Yoshiki 大阪医科大学, 医学部, 講師 (50268207) ; Hayashi Masami 大阪医科大学, 医学部, 講師 (00551748) ; Yoo Saha 大阪医科大学, 医学部, 助教 (80625674) ; Tsunetoh Satoshi 大阪医科大学, 医学部, 講師 (70388255) ; Tanaka Yoshimichi 大阪医科大学, 医学部, 助教 (10625502)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 卵巣癌 / EMT / CD24 / ドラッグデリバリー / 腹膜播種転移 / 薬剤耐性 / 高分子ミセル

Outline of Final Research Achievements

We developed a cisplatin encapsulated polymer micelle targeting (CDDP-CD24-LIPO) of drug delivery system for cisplatin-resistant ovarian cancer cells. We examined the peritoneal dissemination model of cisplatin-resistant ovarian cancer cell lines (Caov3). The cisplatin concentration of disseminated cancer cells with CDDP-CD24-LIPO group was significantly higher than that with CDDP group (p <0.05), the cisplatin concentration in the kidney was significantly lower. Overall survival with CDDP-CD24-LIPO group (71.2 ± 28.3 days) showed a significantly prolonged compared with CDDP group (47.8 ± 7.4 days) (p <0.05). CDDP-CD24-LIPO has enhanced therapeutic effect in refractory ovarian cancer.

Free Research Field

婦人科腫瘍学